Medicus Pharma (NASDAQ:MDCX) Receives Buy Rating from D. Boral Capital

D. Boral Capital restated their buy rating on shares of Medicus Pharma (NASDAQ:MDCX) in a research note published on Monday,Benzinga reports. The brokerage currently has a $27.00 price target on the stock.

Other equities research analysts also recently issued research reports about the company. Maxim Group raised their price target on Medicus Pharma from $10.00 to $20.00 and gave the stock a “buy” rating in a report on Thursday, May 8th. Wall Street Zen raised shares of Medicus Pharma from a “sell” rating to a “hold” rating in a research report on Friday, May 30th. Finally, D Boral Capital raised shares of Medicus Pharma to a “strong-buy” rating in a research report on Monday, April 14th. One equities research analyst has rated the stock with a hold rating, two have assigned a buy rating and two have issued a strong buy rating to the company. According to MarketBeat, the company presently has a consensus rating of “Buy” and an average price target of $23.50.

Medicus Pharma Stock Performance

NASDAQ:MDCX opened at $2.67 on Monday. Medicus Pharma has a one year low of $1.80 and a one year high of $8.94. The firm has a 50-day simple moving average of $4.38 and a 200-day simple moving average of $3.50.

Medicus Pharma (NASDAQ:MDCX) last announced its earnings results on Monday, May 12th. The company reported ($0.42) EPS for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.19). On average, research analysts forecast that Medicus Pharma will post -1.14 earnings per share for the current year.

Insider Buying and Selling

In related news, major shareholder Velocity Fund Partners, Lp sold 75,000 shares of the company’s stock in a transaction that occurred on Tuesday, May 20th. The stock was sold at an average price of $7.72, for a total value of $579,000.00. Following the sale, the insider now owns 3,248,741 shares in the company, valued at $25,080,280.52. This represents a 2.26% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

Hedge Funds Weigh In On Medicus Pharma

A number of institutional investors have recently bought and sold shares of the business. Interchange Capital Partners LLC boosted its holdings in shares of Medicus Pharma by 14.0% in the 1st quarter. Interchange Capital Partners LLC now owns 1,661,871 shares of the company’s stock valued at $6,182,000 after acquiring an additional 204,706 shares during the last quarter. Armistice Capital LLC acquired a new position in Medicus Pharma during the first quarter valued at $4,710,000. Finally, Private Advisor Group LLC purchased a new stake in Medicus Pharma in the first quarter valued at $211,000.

Medicus Pharma Company Profile

Medicus Pharma Ltd is a biotech/life sciences company focused on accelerating the clinical development programs of novel and disruptive therapeutics assets. Medicus Pharma Ltd is based in Toronto, Ontario.